Sotorasib effective in KRAS-mutant NSCLCNon-small-cell lung cancerPhase II trialsTargeted therapiesTumour biomarkersdoi:10.1038/s41571-021-00533-wPeter SidawayNature Reviews Clinical Oncology
Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer Jae-il Roh Jaehoon Lee Han-Woong Lee ArticleOpen Access29 Jul 2020Oncogene Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer...
KRAS mutations are common in non-small cell lung cancer (NSCLC) and are associated with patient prognosis; however, targeting KRAS has faced various difficulties. Currently, immunotherapy, chemotherapy, and chemoimmunotherapy play pivotal roles in the first-line treatment of KRAS-mutated NSCLC. Here,...
mechanisms underlying the resistance to ICIs in NSCLC with KRAS mutation and mainly focus on the role of the tumor microenvironment (TME) and metabolism, therapeutic implications, and potential targets for overcoming the resistance to or improving the efficacy of ICIs treatments in KRAS-mutant NSCLC....
Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high tri
The KRAS oncogene drives many common and highly fatal malignancies. These include pancreatic, lung, and colorectal cancer, where various activating KRAS mutations have made the development of KRAS inhibitors difficult. Here we identify the scaffold prote
KRAS mutationvaccineIntroduction: Cancer develops mainly as a result of accumulating mutations in genes controlling cell growth regulation. RAS is one of the most commonly mutated genes in cancer. While agents targeting the signaling aspects of RAS have met with some success, resistance to therapy ...
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug bi
KRAS-specific inhibitors have shown promising antitumor effects, especially in non-small cell lung cancer, but limited efficacy in colorectal cancer (CRC) patients. Recent studies have shown that EGFR-mediated adaptive feedback mediates primary resistance to KRAS inhibitors, but the ...
Kras-mutant lung cancer model mice (Scgb1a1-Cre;[tetO]-Kras4bG12D;Foxa2flox/flox, a GEMM) and assessed survival and lung histology of the GEMM.Results: Deletion of FOXA2 in autochthonous Kras-mutant lung tumor cells significantly extended the survival of Kras-mutant lung cancer model mice...